Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

551
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
551
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

1.5K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.5K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.0K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.0K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

846
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
846
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

942
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
942
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

910
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
910

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digital transformation and the future of dermatology lectures in 2026 - results of a student survey in Leipzig.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

[Multiple itchy, erythrosquamous skin lesions].

Dermatologie (Heidelberg, Germany)·2026
Same author

Frequency of squamous cell carcinomas in vermilionectomy specimens after confirmed actinic cheilitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

[Generalized pustulosis after leflunomide].

Dermatologie (Heidelberg, Germany)·2026
Same author

[A case of tattoo granuloma treated with topical allopurinol].

Dermatologie (Heidelberg, Germany)·2025
Same author

[Leukonychia following laser therapy for onychomycosis].

Dermatologie (Heidelberg, Germany)·2025
Same journal

The Prevalence of Hospitalized Cases of Necrotizing Fasciitis: Anatomical Distribution, Amputations, and In-Hospital Mortality, 2019-2024.

Deutsches Arzteblatt international·2026
Same journal

Subclinical Atrial Fibrillation: Detection, Stroke Risk, and Treatment.

Deutsches Arzteblatt international·2026
Same journal

Fewer Premature Births After Assisted Reproduction.

Deutsches Arzteblatt international·2026
Same journal

Femoral Artery Pseudoaneurysm Due to Stent Fracture in PAOD.

Deutsches Arzteblatt international·2026
Same journal

Pain-Adapted Full Weight-bearing After Ankle Fracture Surgery: A Multicenter, Pragmatic, Single-armed Prospective Study.

Deutsches Arzteblatt international·2026
Same journal

Popliteal Artery Entrapment Syndrome.

Deutsches Arzteblatt international·2026
See all related articles

Related Experiment Video

Updated: Nov 27, 2025

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.8K

Mucosal Pyoderma Gangrenosum

Aleksander Markovic, Jan Christoph Simon, Manfred Kunz

    Deutsches Arzteblatt International
    |December 2, 2020
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
    05:05

    Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

    Published on: June 17, 2025

    706
    Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
    03:05

    Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

    Published on: February 16, 2024

    1.3K

    Related Experiment Videos

    Last Updated: Nov 27, 2025

    Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
    10:27

    Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

    Published on: December 15, 2011

    24.8K
    Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
    05:05

    Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

    Published on: June 17, 2025

    706
    Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
    03:05

    Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

    Published on: February 16, 2024

    1.3K